Merck & Co., Inc. (MRK)
|Net Income (ttm)||5.57B|
|Ex-Dividend Date||Sep 14, 2021|
|Day's Range||72.57 - 74.04|
|52-Week Range||15.05 - 83.38|
|Price Target||92.42 (+26.5%)|
|Est. Earnings Date||Oct 28, 2021|
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as we... [Read more...]
In 2020, Merck's revenue was $47.99 billion, an increase of 2.46% compared to the previous year's $46.84 billion. Earnings were $7.07 billion, a decrease of -28.20%.Financial Statements
According to 23 analysts, the average rating for Merck stock is "Buy." The 12-month stock price forecast is 92.42, which is an increase of 26.52% from the latest price.
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed Lynparza pl...
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
The stock price of Merck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, and it currently trades at levels of arou...
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in c...
Scoop up these underestimated blue chips while they're not getting much love from the market.
Merck (MRK) closed at $71.93 in the latest trading session, marking a +0.35% move from the prior day.
Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.
Merck & Co Inc (NYSE: MRK) announced the final overall survival (OS) results from the Phase 3 KEYNOTE-355 trial of Keytruda in combination with chemotherapy for the first-line metastatic triple-negative...
The short answer: Yes.
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Tr...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Reduced Risk of Death by 27% Versus Chemo as 1L Treatment for Patients With Metastatic TNBC Whose Tumors Expressed PD L1 (CPS ≥10)
Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Demonstrated Superior Recurrence-Free Survival in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Ve...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Plus Chemo ± Bev Reduced Risk of Death by 33% Vs Chemo ± Bev as Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Pa...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination with Chemo for Certain Patients with Metastatic TNBC
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
The stock price of Merck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, before a recent sell-off in pharmaceutica...
Option Trade: This Put Backspread In Merck Stock Offers Unlimited Upside Potential
For today's trade, we're looking at a put backspread in Merck. This trade profits if the stock stays flat or produces a big drop before expiration and the maximum upside potential is unlimited up to the...
Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Keytruda (...
Not every name Berkshire Hathaway holds is right for all investors, but any of these three picks would be at home in almost any investor's portfolio.
Merck (MRK) closed at $73.18 in the latest trading session, marking a -0.37% move from the prior day.
These large companies still have what it takes to serve up big wins.
Keytruda received its second regulatory approval in China for the treatment of esophageal cancer.